Pulmonx (LUNG) Liabilities and Shareholders Equity (2019 - 2025)

Pulmonx (LUNG) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $129.3 million in Q4 2025.

• Liabilities and Shareholders Equity for Q4 2025 came in at $129.3 million, down 20.61% year-over-year; the trailing twelve-month figure through Dec 2025 was $565.5 million (down 15.28% YoY), and the FY2025 annual result was $129.3 million, down 20.61% from the prior year.
• Liabilities and Shareholders Equity retreated to $129.3 million in Q4 2025 per LUNG's latest filing, from $138.3 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $255.3 million in Q1 2021 and troughed at $129.3 million in Q4 2025.
• A 5-year average of $190.4 million and a median of $189.1 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2021 and 2025: Liabilities and Shareholders Equity jumped 246.44% in 2021, then slipped 20.61% in 2025.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $235.2 million in 2021, then dropped by 17.65% to $193.7 million in 2022, then retreated by 8.21% to $177.8 million in 2023, then slipped by 8.4% to $162.8 million in 2024, then fell by 20.61% to $129.3 million in 2025.
• Business Quant data shows LUNG's Liabilities and Shareholders Equity at $129.3 million in Q4 2025, $138.3 million in Q3 2025, and $147.2 million in Q2 2025.